Business Editors/Health/Medical Writers
CONCORD, Calif.--(BUSINESS WIRE)--May 28, 2003
Cerus Corporation (Nasdaq:CERS) today announced that Timothy B. Anderson, a retired senior vice president of Baxter International Inc., has joined its board of directors. Mr. Anderson joins the board with over 30 years of industry experience, including global commercialization of transfusion medicine products. Mr. Anderson will fill a newly created board seat, raising the current number of directors to seven.
"We are pleased to bring to our board Mr. Anderson's extensive commercialization background and knowledge of the blood banking industry," said Stephen T. Isaacs, president and chief executive officer of Cerus. "His years of experience are valuable to us as we access European markets, and continue to work towards approval of the INTERCEPT Blood System for platelets here in the United States."
Prior to his retirement this year as the senior vice president responsible for corporate strategy and development, a position he held since 1998, Mr. Anderson held various other positions within the Baxter organization. From 1992 to 1998, Mr. Anderson was corporate vice president, and president of the Biotech division where he was instrumental in launching two of Baxter's most successful products: the Amicus Blood Cell Separator and Recombinant Factor VIII. Mr. Anderson was also the president of the Biotherapy group, responsible for the Fenwal and Hyland businesses.
In addition, he worked in various domestic and international management positions before becoming the vice president of Baxter's Asia operations in 1980. Mr. Anderson serves on the board of Lake Forest Hospital and TECAN AG. He holds a bachelor's degree in accounting from Northwestern University and a master's degree in finance and international business from Stanford University.
About Cerus
Cerus Corporation is developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(R) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. The INTERCEPT Blood System, which is being developed in collaboration with subsidiaries of Baxter International Inc. is based on the company's Helinx technology. The INTERCEPT Blood System is designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.
Note to Editors: Helinx is a trademark of Cerus Corporation.
INTERCEPT and INTERCEPT Blood are trademarks of Baxter International Inc.